

***Staphylococcus aureus*, Strain N315**

Catalog No. NR-45898

For research use only. Not for human use.

Contributor:

Keiichi Hiramatsu, MD, PhD, Departments of Microbiology and Infection Control Science, School of Medicine, Jutendo University, Tokyo, Japan

Manufacturer:

BEI Resources

Product Description:**Bacteria Classification:** *Staphylococcaceae*, *Staphylococcus***Species:** *Staphylococcus aureus***Strain:** N315**NARSA Catalog Number:** NRS70**Original Source:** *Staphylococcus aureus* (*S. aureus*), strain N315 was isolated in 1982 from a pharyngeal smear of a patient in Japan.¹

Comments: *S. aureus*, strain N315 is a methicillin-resistant *S. aureus* (MRSA) strain. *S. aureus*, strain N315 was deposited as resistant to clindamycin, erythromycin and spectinomycin; positive for *mec* (subtype II); pulsed-field type USA100; MLST sequence type (ST) 5; eGenomic *spa* type 2, eGenomic *spa* repeats TJMBMDMGMK; Ridom *spa* type t002; *agr* grp II.^{1,3} It also has a large variety of virulence factors.¹ *S. aureus*, strain N315 is a USA100 isolate. USA100 isolates have the same MLST profile (ST 5) and SCC*mec* (subtype II) and are usually resistant to β -lactams, erythromycin and spectinomycin as well as being multiresistant to other commonly used therapeutic agents. USA100 is the most prevalent U.S. health care-associated pulse-field type and is endemic in many U.S. hospitals.³ The complete genome sequence of *S. aureus*, strain N315 is available (GenBank: [BA000018.3](https://www.ncbi.nlm.nih.gov/nuclseq/BA000018.3)). It is the representative genome for *S. aureus*. Note: Methicillin is no longer clinically used, however, the term methicillin-resistant *Staphylococcus aureus* (MRSA) continues to be used to describe *S. aureus* strains resistant to all penicillins.

S. aureus is a Gram-positive, cluster-forming coccus that normally inhabits human nasal passages, skin and mucus membranes. It is also a human pathogen and causes a variety of pus-forming infections as well as food-poisoning and toxic shock syndrome. In 1961, two years after the introduction of methicillin, a penicillinase-resistant penicillin, *S. aureus* developed methicillin-resistance due to acquisition of the *mecA* gene. For the last forty-five years hospital-acquired (HA) MRSA strains have disseminated worldwide. More recently, MRSA strains have been isolated that are not hospital acquired and are referred to as community-associated (CA) MRSA. These CA-MRSA strains differ phenotypically and genotypically from HA-MRSA strains and they are more frequently recovered from skin and soft tissue

sources rather than post-operative wounds.^{4,5}

Material Provided:

Each vial contains approximately 0.5 mL of bacterial culture in Tryptic Soy broth supplemented with 10% glycerol.

Note: If homogeneity is required for your intended use, please purify prior to initiating work.

Packaging/Storage:

NR-45898 was packaged aseptically in cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.

Growth Conditions:**Media:**

Brain Heart Infusion broth or Tryptic Soy broth or equivalent Brain Heart Infusion agar or Tryptic Soy agar with 5% defibrinated sheep blood or equivalent

Incubation:

Temperature: 37°C

Atmosphere: Aerobic

Propagation:

1. Keep vial frozen until ready for use, then thaw.
2. Transfer the entire thawed aliquot into a single tube of broth.
3. Use several drops of the suspension to inoculate an agar slant and/or plate.
4. Incubate the tube, slant and/or plate at 37°C for 18 to 24 hours.

Citation:

Acknowledgment for publications should read "The following reagent was provided by the Network on Antimicrobial Resistance in *Staphylococcus aureus* (NARSA) for distribution by BEI Resources, NIAID, NIH: *Staphylococcus aureus*, Strain N315, NR-45898."

Biosafety Level: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. [Biosafety in Microbiological and Biomedical Laboratories](#). 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Cassat, J. E., et al. "Comparative Genomics of *Staphylococcus aureus* Musculoskeletal Isolates." J. Bacteriol. 187 (2005): 576-592. PubMed: 15629929.
2. NARSA, NRS70.
3. McDougal, L. K., et al. "Pulsed-Field Gel Electrophoresis Typing of Oxacillin-Resistant *Staphylococcus aureus* Isolates from the United States: Establishing a National Database." J Clin Microbiol. 41 (2003): 5113-5120. PubMed: 14605147.
4. Deurenberg, R. H. and E. E. Stobberingh. "The Evolution of *Staphylococcus aureus*." Infect. Genet. Evol. 8 (2008): 747-763. PubMed: 18718557.
5. Davis, S. L., et al. "Epidemiology and Outcomes of Community-Associated Methicillin-Resistant *Staphylococcus aureus* Infection." J. Clin. Microbiol. 45 (2007): 1705-1711. PubMed: 17392441.

ATCC® is a trademark of the American Type Culture Collection.



DIVISION DE PARIS

Paris, le 7 avril 2014

N/Réf. : CODEP-PRS-2014-

Monsieur

Affaire suivie par :

Tél :

Fax :

Mel :

Objet : Autorisation d'exercer une activité nucléaire à des fins non médicales.

Renouvellement et modification : changement de titulaire et regroupement de 2 autorisations de l'IGM.

Réf. : Votre dossier de demande déposé le 20 décembre 2013.

Référence de l'autorisation à rappeler dans toute correspondance : T910250.

Monsieur,

Comme suite à votre demande rappelée en référence et en application de l'article L.1333-4 du code de la santé publique et de l'article L.592-20 du code de l'environnement, je vous prie de trouver ci-joint l'autorisation qui vous a été accordée par l'Autorité de sûreté nucléaire.

Cette autorisation vous permet de détenir et d'utiliser des sources non scellées à des fins de recherche et d'entreposage de sources avant élimination.

La présente autorisation est enregistrée sous le numéro T910250 et expire le 7 avril 2019. Elle met fin aux autorisations précédentes :

- T910299 notifiée le 8 juin 2009 par le courrier référencé Dép-Paris-n°1248-2009 et expirant le 8 juin 2014 ;
- T910250 notifiée le 3 juillet 2009 par le courrier référencé Dép-Paris-n°1509-2009 et expirant le 3 juillet 2014.

Elle peut être déférée devant le Conseil d'Etat dans le délai de deux mois à compter de sa notification.

Elle pourra être renouvelée sur demande adressée à l'Autorité de sûreté nucléaire – Division de Paris, **6 mois avant l'échéance.**

Veillez agréer, Monsieur, l'expression de ma considération distinguée.

Le Chef de la Division de Paris



D. RUEL

www.asn.fr

10, rue Crillon - 75194 Paris cedex 04

Téléphone 01 71 28 44 02 - 01 71 28 44 15 - Fax 01 71 28 46 02

[retour sommaire](#)

Copies :

- IRSN/UES
- Chef d'établissement, Mme C
- Service Hygiène et Sécurité du Travail -
- ISSI -
- Direction DIRHCCTE IDI -
- ..
- BSPP